x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Sequencing Strategies for Second-Line and Beyond...

CME/CE ·

2025/02/06

Guest: Sarah Sammons, MD Guest: Carey Anders, MD, FASCO The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review

en

00:00:00

Optimizing Treatment Selection for HER2+ Breast...

CME/CE ·

2025/02/06

Guest: Carey Anders, MD, FASCO Guest: Sarah Sammons, MD The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review

en

00:00:00

HER2-Targeted TKI Combinations in Second-Line and...

CME/CE ·

2025/02/06

Guest: Sarah Sammons, MD The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing

en

00:00:00

Beyond the Broadcast: Expert Insights on SGLT2...

CME/CE ·

2025/02/04

Host: Melissa Magwire, RN, MSN, CDE Guest: Matthew Bullington, PharmD Guest: Dawn M. Denicola, FNP-C Guest: Keith Miller, MD Are you up to date on the plethora of benefits patients may receive from SGLT2 inhibitors? Learn from a multidisciplinary faculty panel as they use patient case vignettes to review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities such as type 2 diabetes, heart failure, chronic kidney disease, and

en

00:00:00

Current Diagnostic Signs, Symptoms, and Lab Tests for...

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Key Patient Counseling Issues Surrounding FNAIT and...

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Screening for FNAIT: Anticipating HPA-1a Incompatibility

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT):...

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Managing the “Next Pregnancy” in Patients With an...

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

The Alloimmune Disorders of Pregnancy

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Nipocalimab: An FcRn Inhibitor and Its Role in...

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Neonatal FcRn Inhibition: A New Pathway for...

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Current Management Strategies for FNAIT

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Classification/Suspecting a Diagnosis of FNAIT/NAIT

CME/CE ·

2025/01/31

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they

en

00:00:00

Autoantibodies in MG: Their Role in Diagnosis and...

CME/CE ·

2025/01/17

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James

en

00:00:00

Balancing Risk and Benefit: Traditional MG Treatments...

CME/CE ·

2025/01/17

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James

en

00:00:00

Beyond the Symptoms: The True Impact of gMG on...

CME/CE ·

2025/01/17

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James

en

00:00:00

The Science Behind FcRn Antagonists: A Deep Dive Into...

CME/CE ·

2025/01/17

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James

en

00:00:00

Precision Medicine in Myasthenia Gravis: Crafting...

CME/CE ·

2025/01/17

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James

en

00:00:00

FcRn Antagonists in Myasthenia Gravis: A New Era in...

CME/CE ·

2025/01/17

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James

en

286 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事